News & Events 2016
28 July 2016
Incepta Vaccine Ltd has launched its vaccine bulk manufacturing facility in Savar, Dhaka. Honorable health Minister Mohammed Nasim, MP inaugurated the facility on Thursday, 28 July 2016.
Incepta Vaccine Ltd has developed an international standard bulk manufacturing facility providing the best environmental condition for performing the operations. The facility can manufacture both Bacterial and Viral bulk antigens. These will make us less dependent on vaccine import and help us to become a self-sufficient vaccine manufacturing country.
Addressing the inaugural ceremony, the minister said that Bangladesh is now able to export quality medicines to 90 countries all over the globe. Bangladesh is now capable of manufacturing life saving vaccine and successfully reduces the dependency on imported vaccines. ‘We will take the initiatives to get the WHO authorization which is needed for export of vaccines.’ The minister said.
Director General of Drug Administration, Major General Md Mustafizur Rahman and Secretary General of Bangladesh Association of Pharmaceutical Industries, SM Shafiuzzaman were also present there as special guests.
Incepta Vaccine Ltd has developed an international standard bulk manufacturing facility providing the best environmental condition for performing the operations. The facility can manufacture both Bacterial and Viral bulk antigens. These will make us less dependent on vaccine import and help us to become a self-sufficient vaccine manufacturing country.
Addressing the inaugural ceremony, the minister said that Bangladesh is now able to export quality medicines to 90 countries all over the globe. Bangladesh is now capable of manufacturing life saving vaccine and successfully reduces the dependency on imported vaccines. ‘We will take the initiatives to get the WHO authorization which is needed for export of vaccines.’ The minister said.
Director General of Drug Administration, Major General Md Mustafizur Rahman and Secretary General of Bangladesh Association of Pharmaceutical Industries, SM Shafiuzzaman were also present there as special guests.
14 June 2016
As medicine progresses into a new era of personalized therapy, the use of monoclonal antibodies to treat a wide range of diseases lies at the heart of this new forefront. Monoclonal antibodies (mAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies recognize and attach to specific proteins produced by cells. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting. Nowadays, there are approximately 30 monoclonal antibodies that have been approved for use in clinical practice in world market with many more currently being tested in clinical trials. Treatment landscape for monoclonal antibodies includes cancer, Osteoporosis, Rheumatoid Arthritis, Asthma, Psoriasis, Spondylitis, Inflammatory Bowel Disease etc.
Incepta pharmaceuticals Ltd, one of the leading pharmaceutical company in Bangladesh, is now manufacturing three monoclonal antibodies for the treatment of Osteoporosis, Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Disease, Non Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia etc. Since its inception, Incepta has always pioneered in launching many first ever manufactured drugs in Bangladesh market. To continue its legacy, Incepta has launched 3 mAbs with brand name Relyto 100 & 500 (Rituximab), Denosis 60 & 120 (Denosumab) and Advixa (Adalimumab). True to its vision to become a trusted healthcare company that provides better health for everyone, everywhere, Incepta has launched these drugs to ensure better health for thousands of patients suffering from disease conditions like Osteoporosis, Arthritis, and Spondylitis etc.
Osteoporosis is a medical condition in which the bones become brittle and fragile from loss of tissue, typically as a result of hormonal changes, or deficiency of Calcium or vitamin D. Rheumatoid Arthritis is a chronic progressive disease causing inflammation in the joints and resulting in painful deformity and immobility, especially in the fingers, wrists, feet, and ankles. Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues (such as the spleen and bone marrow) whereas chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets. Thousands of patients are suffering from these debilitating diseases. Quality of life is significantly hampered, even the simplest tasks like drinking a glass of water becomes difficult. It is to be noted that Adalimumab is the best-selling drug in the world. Millions of patients worldwide are taking this mAbs for conditions like Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Diseases etc. Denosumab is used for Osteoporosis and to reduce bone fracture risk in those who have risk factors. Relyto is used for Non Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Incepta pharmaceuticals will continue to launch newer and better drug for the betterment of patients. Its pipeline includes many anticancer drugs including many mAbs and Tinibs. These drugs are known as targeted therapy for cancer. There are about 15 lakh cancer patients in Bangladesh, where about 2 lakh patients newly adding every year in this pool. In the coming years, the increase in population and longevity will result in an increase in the number of cancer patients in Bangladesh. With the launching of all these drugs Incepta hope to achieve new frontiers in cancer treatment regimen.
Incepta pharmaceuticals Ltd, one of the leading pharmaceutical company in Bangladesh, is now manufacturing three monoclonal antibodies for the treatment of Osteoporosis, Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Disease, Non Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia etc. Since its inception, Incepta has always pioneered in launching many first ever manufactured drugs in Bangladesh market. To continue its legacy, Incepta has launched 3 mAbs with brand name Relyto 100 & 500 (Rituximab), Denosis 60 & 120 (Denosumab) and Advixa (Adalimumab). True to its vision to become a trusted healthcare company that provides better health for everyone, everywhere, Incepta has launched these drugs to ensure better health for thousands of patients suffering from disease conditions like Osteoporosis, Arthritis, and Spondylitis etc.
Osteoporosis is a medical condition in which the bones become brittle and fragile from loss of tissue, typically as a result of hormonal changes, or deficiency of Calcium or vitamin D. Rheumatoid Arthritis is a chronic progressive disease causing inflammation in the joints and resulting in painful deformity and immobility, especially in the fingers, wrists, feet, and ankles. Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues (such as the spleen and bone marrow) whereas chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets. Thousands of patients are suffering from these debilitating diseases. Quality of life is significantly hampered, even the simplest tasks like drinking a glass of water becomes difficult. It is to be noted that Adalimumab is the best-selling drug in the world. Millions of patients worldwide are taking this mAbs for conditions like Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Diseases etc. Denosumab is used for Osteoporosis and to reduce bone fracture risk in those who have risk factors. Relyto is used for Non Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Incepta pharmaceuticals will continue to launch newer and better drug for the betterment of patients. Its pipeline includes many anticancer drugs including many mAbs and Tinibs. These drugs are known as targeted therapy for cancer. There are about 15 lakh cancer patients in Bangladesh, where about 2 lakh patients newly adding every year in this pool. In the coming years, the increase in population and longevity will result in an increase in the number of cancer patients in Bangladesh. With the launching of all these drugs Incepta hope to achieve new frontiers in cancer treatment regimen.
